Psoriasis is a chronic systemic inflammatory skin disorder prevailing in 2%–3% individuals worldwide. Yet no permanent management has been established. Metabolic burdens and comorbidities have been found to be associated with Psoriasis, which make it more critical. The classical management of the disease in Ayurveda includes Vamana Karma (therapeutic emesis) and Virechana Karma (therapeutic purgation). This is a distinct case where a 52-year-old patient, suffering from Chronic Plaque Psoriasis (CPP), unfit for Vamana Karma was treated by VirechanaKarma only. The patient had suffered from Psoriasis since last 14 years and was present with symptoms of scaly lesions and intense itching. The patient was admitted in the IPD and planned for Virechana Karma. After Shodhana, Rasamanikya-125 mg, Vidanga Choorna 2 gm, Kaishora Guggulu-1000 mg, Kamdudha Rasa 250 mg, Khadirarishta-20 ml, and Punarnavadi Kwatha 40 ml, twice a day was advised with daily 3 times local application of Bruhad Marichyadi Taila as regular medication. The assessment was done by Psoriasis Area Severity Index (PASI) score, Dermatology Life Quality Index (DLQI) score and Numerical Rating Scale (NRS) for itching. The initial PASI, DLQI and NRS scores were 20.6, 18, and 8 respectively which was evaluated to be, 5.8, 4 and 2 respectively in the latest follow-up. This case study demonstrates that Virechana alone may also manage CPP.
{"title":"Management of Chronic Plaque Psoriasis through Panchkarma: A case report","authors":"Rohan Agalcha, Sarvesh Kumar Singh, Kshipra Rajoria","doi":"10.1016/j.jaim.2024.101072","DOIUrl":"10.1016/j.jaim.2024.101072","url":null,"abstract":"<div><div>Psoriasis is a chronic systemic inflammatory skin disorder prevailing in 2%–3% individuals worldwide. Yet no permanent management has been established. Metabolic burdens and comorbidities have been found to be associated with Psoriasis, which make it more critical. The classical management of the disease in Ayurveda includes <em>Vamana Karma</em> (therapeutic emesis) and <em>Virechana Karma</em> (therapeutic purgation). This is a distinct case where a 52-year-old patient, suffering from Chronic Plaque Psoriasis (CPP), unfit for <em>Vamana Karma</em> was treated by <em>Virechana</em> <em>Karma</em> only. The patient had suffered from Psoriasis since last 14 years and was present with symptoms of scaly lesions and intense itching. The patient was admitted in the IPD and planned for <em>Virechana Karma</em>. After <em>Shodhana</em>, <em>Rasamanikya</em>-125 mg, <em>Vidanga Choorna</em> 2 gm, <em>Kaishora Guggulu</em>-1000 mg, <em>Kamdudha Rasa</em> 250 mg, <em>Khadiraris</em><em>h</em><em>ta</em>-20 ml, and <em>Punarnavadi Kwatha</em> 40 ml, twice a day was advised with daily 3 times local application of <em>Bruhad Marichyadi Taila</em> as regular medication. The assessment was done by Psoriasis Area Severity Index (PASI) score, Dermatology Life Quality Index (DLQI) score and Numerical Rating Scale (NRS) for itching. The initial PASI, DLQI and NRS scores were 20.6, 18, and 8 respectively which was evaluated to be, 5.8, 4 and 2 respectively in the latest follow-up. This case study demonstrates that <em>Virechana</em> alone may also manage CPP.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"16 1","pages":"Article 101072"},"PeriodicalIF":1.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11787006/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Male breast cancer (MBC) is an uncommon malignancy. In spite of conventional Allopathic treatment, long-term disease-free survival (DFS) of more than 10 years in MBC is rare, due to its aggressive nature.
Case presentation
We report a case of 56 years old, stage IIB and grade III invasive ductal cell carcinoma MBC (Lt) patient, operated for left modified radical mastectomy with axillary clearance followed by six cycles of chemotherapy during October 2010–January 2011. Patient was on hormonal treatment from March 2011 till May 2021. He opted for adjunct Ayurvedic treatment throughout the conventional treatments for the period of 10 years. Ayurvedic treatment in the form of treatment for pacifying imbalanced humors (Doshas) and disease (Shamana chikitsa) and treatment for immunomodulation (Rasayana Chikitsa); and periodic detoxifying treatment (Panchakarma Chikitsa) was given in this patient. He was also advised healthy diet and lifestyle at our center. The treatment chosen was mainly to reduce side effects of chemotherapy like anorexia, nausea, vomiting, constipation, diarrhoea, taste disturbance, mucositis, fatigue and fever. It also helped in improving quality of life and increasing DFS.
Conclusion
The long DFS of 10 years and 3 months with good Quality of Life and minimal side effects of conventional cancer therapy could be ascribed to the adjunct Ayurvedic treatment given to this patient. We have to observe the benefits in more number of patients in future to define usefulness of this treatment modality.
{"title":"Adjunct Ayurvedic treatment providing more than 10 years of disease-free survival in a rare case of male breast cancer patient with high-grade invasive ductal cell carcinoma - A Case Report","authors":"Vineeta Deshmukh, Sadanand Sardeshmukh, Arvind Kulkarni, Vidya Gupta, Shweta Gujar, Bhagyashree Sardeshmukh, Nilambari Sardeshmukh, Dhananjay Deshpande, Keyur Gutte, Vinita Awalkanthe, Anjali Deshpande, Shrikant Kulkarni","doi":"10.1016/j.jaim.2024.100982","DOIUrl":"10.1016/j.jaim.2024.100982","url":null,"abstract":"<div><h3>Introduction</h3><div>Male breast cancer (MBC) is an uncommon malignancy. In spite of conventional Allopathic treatment, long-term disease-free survival (DFS) of more than 10 years in MBC is rare, due to its aggressive nature.</div></div><div><h3>Case presentation</h3><div>We report a case of 56 years old, stage IIB and grade III invasive ductal cell carcinoma MBC (Lt) patient, operated for left modified radical mastectomy with axillary clearance followed by six cycles of chemotherapy during October 2010–January 2011. Patient was on hormonal treatment from March 2011 till May 2021. He opted for adjunct <em>Ayurvedic</em> treatment throughout the conventional treatments for the period of 10 years. Ayurvedic treatment in the form of treatment for pacifying imbalanced humors (<em>Doshas</em>) and disease (<em>Shamana chikitsa</em>) and treatment for immunomodulation (<em>Rasayana Chikitsa</em>); and periodic detoxifying treatment (<em>Panchakarma Chikitsa</em>) was given in this patient. He was also advised healthy diet and lifestyle at our center. The treatment chosen was mainly to reduce side effects of chemotherapy like anorexia, nausea, vomiting, constipation, diarrhoea, taste disturbance, mucositis, fatigue and fever. It also helped in improving quality of life and increasing DFS.</div></div><div><h3>Conclusion</h3><div>The long DFS of 10 years and 3 months with good Quality of Life and minimal side effects of conventional cancer therapy could be ascribed to the adjunct Ayurvedic treatment given to this patient. We have to observe the benefits in more number of patients in future to define usefulness of this treatment modality.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"16 1","pages":"Article 100982"},"PeriodicalIF":1.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.jaim.2024.101037
Aalina Sakiinah Mohd Fuad , Mohd Hafiz Arzmi , Muhammad Ekmal Bakar , Izatus Shima Taib , Fazle Khuda , Nurrul Shaqinah Nasruddin
Background
The combination of S. salivarius K12 and M. acuminata are being used as synbiotic, but its safety evaulation is required.
Objective
This study aimed to determine the LD50 of synbiotic containing probiotic Streptococcus salivarius K12 and prebiotic Musa acuminata peel extract.
Materials and Methods
The determination of LD50 is done according to the Acute Oral Toxicity test No. 425 (AOT425). For limit test, five female Sprague Dawley rats were given a limit dose of 2000 mg/kg of the synbiotic mixture once orally, and observed for 12 days. For subacute toxicity test, twenty female Sprague Dawley rats were randomised into 4 groups (n = 5). Control group received saline, others received synbiotic mixture at doses 175 mg/kg, 550 mg/kg, and 2000 mg/kg, respectively, and observed for 14 days. Animals were euthanised on day-15, blood was collected, and subjected to haematological and biochemical analyses. Kidney and liver were preserved for histopathological examination.
Result
No significant changes on the average body weight of the animals throughout the study. Haematological parameters and biochemical analysis do not depict any changes related to acute toxicity. Histopathology analysis depicted mild changes on kidney and liver.
Conclusion
Based on the data, the LD50 of the synbiotic formulation is higher than 2000 mg/kb, with no sign of acute toxicity observed on all parameters.
{"title":"Acute oral toxicity evaluation of synbiotic mixture containing Streptococcus salivarius K12 and Musa acuminata aqueous peel extract in Sprague-Dawley rats","authors":"Aalina Sakiinah Mohd Fuad , Mohd Hafiz Arzmi , Muhammad Ekmal Bakar , Izatus Shima Taib , Fazle Khuda , Nurrul Shaqinah Nasruddin","doi":"10.1016/j.jaim.2024.101037","DOIUrl":"10.1016/j.jaim.2024.101037","url":null,"abstract":"<div><h3>Background</h3><div>The combination of S. salivarius K12 and M. acuminata are being used as synbiotic, but its safety evaulation is required.</div></div><div><h3>Objective</h3><div>This study aimed to determine the LD50 of synbiotic containing probiotic <em>Streptococcus salivarius</em> K12 and prebiotic <em>Musa acuminata</em> peel extract.</div></div><div><h3>Materials and Methods</h3><div>The determination of LD50 is done according to the Acute Oral Toxicity test No. 425 (AOT425). For limit test, five female Sprague Dawley rats were given a limit dose of 2000 mg/kg of the synbiotic mixture once orally, and observed for 12 days. For subacute toxicity test, twenty female Sprague Dawley rats were randomised into 4 groups (n = 5). Control group received saline, others received synbiotic mixture at doses 175 mg/kg, 550 mg/kg, and 2000 mg/kg, respectively, and observed for 14 days. Animals were euthanised on day-15, blood was collected, and subjected to haematological and biochemical analyses. Kidney and liver were preserved for histopathological examination.</div></div><div><h3>Result</h3><div>No significant changes on the average body weight of the animals throughout the study. Haematological parameters and biochemical analysis do not depict any changes related to acute toxicity. Histopathology analysis depicted mild changes on kidney and liver.</div></div><div><h3>Conclusion</h3><div>Based on the data, the LD50 of the synbiotic formulation is higher than 2000 mg/kb, with no sign of acute toxicity observed on all parameters.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"16 1","pages":"Article 101037"},"PeriodicalIF":1.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11714393/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142835777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background:Garuga pinnata Roxb., a member of family Burseraceae, is a commonly grown plant in south east Asia including India in tropical rain forests predominately. Apart from folkloric use, important anti-inflammatory and antiasthamatic activity of this plant has been revealed. Objective: This study is aimed to know neuroprotective effects of ethanolic extracts which is based on the computationally determined NMDA as molecular target. Material and Methods: Well dried ethanolic extract of leaves was examined for the presence of amentoflavone with LC-MS/MS which offered the fragments those mimicked the fragmentation of amentoflavone. Effect of ethanolic extract was studies by dividing experimental rat groups each consisting of six animals into sham group, control group, GPE 200 mg/kg and GPE 400 mg/kg groups and were operated for hassle free administration of colchicine. The pharmacological study involved Morris water maze test, Elevated plus maze test and Open Field Box Test. Results: In Morris water maze test, both the selected doses of extracts showed significant decrease in the mean escape latencies upon colchicine challenge. Similarly, in both the doses of the extract showed improved motor and grooming effects in elevated plus maze test upon colchicine injection and also significant ambulatory movements were recorded in open field box test too. Conclusion: The ethanolic extracts of Garuga pinnata on the experimental animals showed significant restoration of the memory capacity of the tested animals, thus the computationally explored insights and pharmco-behavioral screening were quite closure to each other.
{"title":"Molecular dynamics directed neuroprotective activity of alcoholic extract of Garuga pinnata Roxb. in experimental rats","authors":"Shinge Jagannath , Walhekar Vinayak , Muthal Amol , Pamu Sandhya , Chandrashekar V.M , Shinde Vaibhav , Ravindra Kulkarni","doi":"10.1016/j.jaim.2024.101032","DOIUrl":"10.1016/j.jaim.2024.101032","url":null,"abstract":"<div><div><strong>Background:</strong> <em>Garuga pinnata</em> Roxb., a member of family Burseraceae, is a commonly grown plant in south east Asia including India in tropical rain forests predominately. Apart from folkloric use, important anti-inflammatory and antiasthamatic activity of this plant has been revealed. <strong>Objective:</strong> This study is aimed to know neuroprotective effects of ethanolic extracts which is based on the computationally determined NMDA as molecular target. <strong>Material and Methods:</strong> Well dried ethanolic extract of leaves was examined for the presence of amentoflavone with LC-MS/MS which offered the fragments those mimicked the fragmentation of amentoflavone. Effect of ethanolic extract was studies by dividing experimental rat groups each consisting of six animals into sham group, control group, GPE 200 mg/kg and GPE 400 mg/kg groups and were operated for hassle free administration of colchicine. The pharmacological study involved Morris water maze test, Elevated plus maze test and Open Field Box Test. <strong>Results:</strong> In Morris water maze test, both the selected doses of extracts showed significant decrease in the mean escape latencies upon colchicine challenge. Similarly, in both the doses of the extract showed improved motor and grooming effects in elevated plus maze test upon colchicine injection and also significant ambulatory movements were recorded in open field box test too. <strong>Conclusion:</strong> The ethanolic extracts of <em>Garuga pinnata</em> on the experimental animals showed significant restoration of the memory capacity of the tested animals, thus the computationally explored insights and pharmco-behavioral screening were quite closure to each other.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"16 1","pages":"Article 101032"},"PeriodicalIF":1.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11748729/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.jaim.2024.101049
Boyagoda Vidanelage Loshini Ravima Ranaweera , Daniya Edward , Jayamini Chathurika Harasgama , Ajita Mahendra Abeysekera , Ovitigala Vithanage Don Sisira Jagathpriya Weerasena , Shiroma Mangalika Handunnetti
Background
Link Samahan® (LS), a product of Link Natural Products (Pvt) Limited, Sri Lanka contains extracts of 14 medicinal plants. It is used as a prophylactic against cold and cold related symptoms. It has immunomodulatory activity, specifically enhancing the humoral immune response.
Objective
To investigate the anti-inflammatory activity (AIA) of LS and related mechanisms.
Materials and methods
In vivo AIA was assessed by the inhibition of carrageenan-induced rat paw-edema. Mechanisms of AIA were assessed in vitro by the inhibition of reactive oxygen species (ROS) and reactive nitrogen species (RNS) production and expression of inducible nitric oxide synthase (iNOS) gene using rat peritoneal cells.
Results
LS showed an increasing inhibition in rat paw-edema up to 5 h compared to the biphasic pattern exhibited by the reference drug, Indomethacin. Inhibition by LS at the 1st and 3rd-5th hours (44.7% and 73.0–74.6%) was comparable to indomethacin (47.4% and 83.6–76.5%; p > 0.05) whereas at the 2nd hour, LS exhibited a significantly higher inhibition compared to indomethacin (66.7% vs 28.6%; p < 0.05). LS treatment significantly inhibited the ROS (superoxide; 47.2 ± 0.86%; p < 0.05) and RNS (nitrite; 54.0 ± 0.40%; p < 0.05) production in rat peritoneal cells. Further, specific inhibition of iNOS gene expression in rat peritoneal cells resulted in a significant reduction in RNS production whereas LS had lesser or no inhibitory effect on endothelial NOS and neuronal NOS gene expression.
Conclusion
LS has potent anti-inflammatory activity and selective inhibition of iNOS activity. AIA of LS shown here supports its use as a prophylactic against cold and cold related symptoms.
{"title":"Anti-inflammatory activity and selective inhibition of iNOS gene expression by a polyherbal formulation","authors":"Boyagoda Vidanelage Loshini Ravima Ranaweera , Daniya Edward , Jayamini Chathurika Harasgama , Ajita Mahendra Abeysekera , Ovitigala Vithanage Don Sisira Jagathpriya Weerasena , Shiroma Mangalika Handunnetti","doi":"10.1016/j.jaim.2024.101049","DOIUrl":"10.1016/j.jaim.2024.101049","url":null,"abstract":"<div><h3>Background</h3><div>Link Samahan® (LS), a product of Link Natural Products (Pvt) Limited, Sri Lanka contains extracts of 14 medicinal plants. It is used as a prophylactic against cold and cold related symptoms. It has immunomodulatory activity, specifically enhancing the humoral immune response.</div></div><div><h3>Objective</h3><div>To investigate the anti-inflammatory activity (AIA) of LS and related mechanisms.</div></div><div><h3>Materials and methods</h3><div><em>In vivo</em> AIA was assessed by the inhibition of carrageenan-induced rat paw-edema. Mechanisms of AIA were assessed <em>in vitro</em> by the inhibition of reactive oxygen species (ROS) and reactive nitrogen species (RNS) production and expression of inducible nitric oxide synthase (iNOS) gene using rat peritoneal cells.</div></div><div><h3>Results</h3><div>LS showed an increasing inhibition in rat paw-edema up to 5 h compared to the biphasic pattern exhibited by the reference drug, Indomethacin. Inhibition by LS at the 1<sup>st</sup> and 3<sup>rd</sup>-5<sup>th</sup> hours (44.7% and 73.0–74.6%) was comparable to indomethacin (47.4% and 83.6–76.5%; p > 0.05) whereas at the 2<sup>nd</sup> hour, LS exhibited a significantly higher inhibition compared to indomethacin (66.7% vs 28.6%; p < 0.05). LS treatment significantly inhibited the ROS (superoxide; 47.2 ± 0.86%; p < 0.05) and RNS (nitrite; 54.0 ± 0.40%; p < 0.05) production in rat peritoneal cells. Further, specific inhibition of iNOS gene expression in rat peritoneal cells resulted in a significant reduction in RNS production whereas LS had lesser or no inhibitory effect on endothelial NOS and neuronal NOS gene expression.</div></div><div><h3>Conclusion</h3><div>LS has potent anti-inflammatory activity and selective inhibition of iNOS activity. AIA of LS shown here supports its use as a prophylactic against cold and cold related symptoms.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"16 1","pages":"Article 101049"},"PeriodicalIF":1.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11787581/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Prolapsed intervertebral disc (PIVD) can lead to debilitating pain and functional limitations. While surgical interventions like Transforaminal Lumbar Interbody Fusion (TLIF) are often employed, recurrence of symptoms is not uncommon. This case report presents the successful Ayurvedic management of a 45-year-old female who developed recurrent lumbar radiculopathy six months after TLIF for PIVD.
The patient presented with severe lumbar pain, disability, and bilateral leg discomfort. Diagnosed with “Prushthagraha” according to Ayurvedic principles, she underwent a 43-day treatment regimen. This included Ayurvedic medications and an initial eight-day course of Sarvanga Abhyanga-Mardana (therapeutic massage) and Swedana (sudation therapy).
Post-treatment, the patient demonstrated significant clinical improvement, evidenced by a substantial reduction in Oswestry Disability Index (ODI) and Visual Analogue Scale (VAS) scores for both lumbar and leg pain. Furthermore, her walking distance increased from 80 m to 1000 m.
This case highlights the potential of Ayurvedic interventions as a complementary approach for managing recurrent lumbar radiculopathy following surgical intervention for PIVD. However, further research with larger sample sizes and controlled study designs is warranted to validate these findings.
{"title":"Ayurvedic management of recurrent lumbar pain, disability, and leg pain after posterior decompression with transforaminal lumbar interbody fusion in prolapsed intervertebral disc: A case report","authors":"Satyajit Pandurang Kulkarni , Pallavi Satyajit Kulkarni","doi":"10.1016/j.jaim.2024.101071","DOIUrl":"10.1016/j.jaim.2024.101071","url":null,"abstract":"<div><div>Prolapsed intervertebral disc (PIVD) can lead to debilitating pain and functional limitations. While surgical interventions like Transforaminal Lumbar Interbody Fusion (TLIF) are often employed, recurrence of symptoms is not uncommon. This case report presents the successful Ayurvedic management of a 45-year-old female who developed recurrent lumbar radiculopathy six months after TLIF for PIVD.</div><div>The patient presented with severe lumbar pain, disability, and bilateral leg discomfort. Diagnosed with “Prushthagraha” according to Ayurvedic principles, she underwent a 43-day treatment regimen. This included Ayurvedic medications and an initial eight-day course of Sarvanga Abhyanga-Mardana (therapeutic massage) and Swedana (sudation therapy).</div><div>Post-treatment, the patient demonstrated significant clinical improvement, evidenced by a substantial reduction in Oswestry Disability Index (ODI) and Visual Analogue Scale (VAS) scores for both lumbar and leg pain. Furthermore, her walking distance increased from 80 m to 1000 m.</div><div>This case highlights the potential of Ayurvedic interventions as a complementary approach for managing recurrent lumbar radiculopathy following surgical intervention for PIVD. However, further research with larger sample sizes and controlled study designs is warranted to validate these findings.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"16 1","pages":"Article 101071"},"PeriodicalIF":1.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11786815/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.jaim.2024.101043
Bhavya Vijay , Poornima Devkumar , Gargi Saha , Satish P. RamachandraRao
Background
Obesity is a rising risk factor for various diseases including cardiovascular diseases and Cancer. The limitations of targeted obesity-treatment approaches employed in the clinic presently underscore the importance of developing integrative management strategies for identification of specific biomarkers of obesity. Objectives: Given the specificity of exosome/extracellular vesicle (EV) biomarkers, we aimed here to identify the EV biomarkers of Ayurveda treatment – Lekhana Basti – for Obesity.
Methodology
A total of eighteen 24-h urine samples from 6 participants with BMI>30 kg/m2 were used in this study, collected over 3 time-points during the Lekhana basti (medicated enema for obesity) treatment. Urine EV were isolated using Polyethylene Glycol (PEG). The proteins were resolved by 1-d gel electrophoresis and identified using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) and quantified by label-free methods. Significant Protein-Protein Interactions, KEGG pathway analysis and enrichment, functional gene ontology (GO) annotation were identified and shortlisted in comparison to Obesity reference genes from DisGeNET.
Results
With UniProt as a reference subsequent to LC-MS/MS-identification, a total of 210 exosome proteins were identified. Seventy-three proteins were overexpressed in pathway enrichment analysis. Further, GO functional annotation identified 15 common proteins involved. Finally, the 8 hub proteins associated with obesity were identified and their differential expression profile compared between three different time-points during Lekhana Basti treatment. Six protein markers overexpressed during obesity were downregulated post Lekhana Basti treatment, while 2 markers increased in abundance post-treatment.
Conclusion
To our knowledge, this is the first study to isolate and identify urine EV protein abundance profiles from obese female participants of India. The study results indicate significant changes in the differential expression profile of 8 hub proteins involved in obesity, after Lekhana Basti treatment. The biomarker signature of the pilot study indicates the role of Ayurveda treatment and the possible pathways involved in the treatment of Obesity. Further, this study underlines the specificity of urine exosomes/EV as diagnostic markers as well as the potential of Ayurveda treatment in effective management of obesity.
{"title":"Urine exosome biomarkers of obesity after Lekhana Basti treatment – Report of a pilot study","authors":"Bhavya Vijay , Poornima Devkumar , Gargi Saha , Satish P. RamachandraRao","doi":"10.1016/j.jaim.2024.101043","DOIUrl":"10.1016/j.jaim.2024.101043","url":null,"abstract":"<div><h3>Background</h3><div>Obesity is a rising risk factor for various diseases including cardiovascular diseases and Cancer. The limitations of targeted obesity-treatment approaches employed in the clinic presently underscore the importance of developing integrative management strategies for identification of specific biomarkers of obesity. <strong>Objectives:</strong> Given the specificity of exosome/extracellular vesicle (EV) biomarkers, we aimed here to identify the EV biomarkers of Ayurveda treatment – <em>Lekhana Basti</em> – for Obesity.</div></div><div><h3>Methodology</h3><div>A total of eighteen 24-h urine samples from 6 participants with BMI>30 kg/m<sup>2</sup> were used in this study, collected over 3 time-points during the Lekhana basti (medicated enema for obesity) treatment. Urine EV were isolated using Polyethylene Glycol (PEG). The proteins were resolved by 1-d gel electrophoresis and identified using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) and quantified by label-free methods. Significant Protein-Protein Interactions, KEGG pathway analysis and enrichment, functional gene ontology (GO) annotation were identified and shortlisted in comparison to Obesity reference genes from DisGeNET.</div></div><div><h3>Results</h3><div>With UniProt as a reference subsequent to LC-MS/MS-identification, a total of 210 exosome proteins were identified. Seventy-three proteins were overexpressed in pathway enrichment analysis. Further, GO functional annotation identified 15 common proteins involved. Finally, the 8 hub proteins associated with obesity were identified and their differential expression profile compared between three different time-points during <em>Lekhana Basti</em> treatment. Six protein markers overexpressed during obesity were downregulated post <em>Lekhana Basti</em> treatment, while 2 markers increased in abundance post-treatment.</div></div><div><h3>Conclusion</h3><div>To our knowledge, this is the first study to isolate and identify urine EV protein abundance profiles from obese female participants of India. The study results indicate significant changes in the differential expression profile of 8 hub proteins involved in obesity, after <em>Lekhana Basti</em> treatment. The biomarker signature of the pilot study indicates the role of Ayurveda treatment and the possible pathways involved in the treatment of Obesity. Further, this study underlines the specificity of urine exosomes/EV as diagnostic markers as well as the potential of Ayurveda treatment in effective management of obesity.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"16 1","pages":"Article 101043"},"PeriodicalIF":1.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143065826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Triple-negative breast cancer (TNBC) is a subtype of breast cancer clinically defined as lacking expression of Estrogen receptor (ER), Progesterone receptor (PR), and Human Epidermal growth factor Receptor (HER2). Psychological distress is a major risk factor of TNBC, patients diagnosed with TNBC are under tremendous stress due to the aggressive nature of the disease. Stress hormones decrease the efficacy of therapeutics. These facts underscore the need for mind relaxation treatment for TNBC patients.
Objectives
To find out the anti-anxiety activity of the Jatamansi Taila in TNBC patients.
Material and methods
This was a two-arm, open-labelled, parallel, prospective controlled clinical study, conducted on 70 patients of TNBC in the age group of 20–70 years who have completed conventional therapy and opted for Ayurvedic Treatment. Patients were divided into 2 groups. Thirty-five patients in Group A were treated with Oral Ayurvedic Medicines (Shamana Chikitsa) and Jatamansi Taila Shirodhara; whereas 35 patients in Group B were treated with only Oral Ayurvedic Medicines.
Results
Jatamansi Taila Shirodhara was found to be effective in relieving symptoms of Anxiety and Psychological distress (Chittodvega) immediately after the procedure, viz. sleep disturbance, difficulty in concentration, and fearfulness. Jatamansi Taila Shirodhara was found to be highly effective in improving Quality of Life (QoL), especially in improving functional ability, well-being and reducing symptomatology related to breast cancer, measured by scores of QLQ C30 and symptom score of QLQ BR23.
Conclusion
This study emphasizes the role of Jatamansi Taila Shirodhara therapy for mind and body relaxation in psychological distress seen in breast cancer especially, in TNBC patients.
{"title":"Mind relaxation effect of Jatamansi Taila Shirodhara on psychological distress in Triple Negative Breast Cancer (TNBC) patients - results of an open-labelled, randomised controlled clinical trial","authors":"Sadanand Sardeshmukh , Vineeta Deshmukh , Vasanti Godse , Anaya Pathrikar , Abhijeet Joshi , Shweta Gujar , Bhagyashri Sardeshmukh , Anjali Deshpande , Sushama Bhuvad","doi":"10.1016/j.jaim.2024.101069","DOIUrl":"10.1016/j.jaim.2024.101069","url":null,"abstract":"<div><h3>Background</h3><div>Triple-negative breast cancer (TNBC) is a subtype of breast cancer clinically defined as lacking expression of Estrogen receptor (ER), Progesterone receptor (PR), and Human Epidermal growth factor Receptor (HER2). Psychological distress is a major risk factor of TNBC, patients diagnosed with TNBC are under tremendous stress due to the aggressive nature of the disease. Stress hormones decrease the efficacy of therapeutics. These facts underscore the need for mind relaxation treatment for TNBC patients.</div></div><div><h3>Objectives</h3><div>To find out the anti-anxiety activity of the <em>Jatamansi Taila</em> in TNBC patients.</div></div><div><h3>Material and methods</h3><div>This was a two-arm, open-labelled, parallel, prospective controlled clinical study, conducted on 70 patients of TNBC in the age group of 20–70 years who have completed conventional therapy and opted for Ayurvedic Treatment. Patients were divided into 2 groups. Thirty-five patients in Group A were treated with Oral Ayurvedic Medicines (<em>Shamana Chikitsa</em>) and <em>Jatamansi Taila Shirodhara</em>; whereas 35 patients in Group B were treated with only Oral Ayurvedic Medicines.</div></div><div><h3>Results</h3><div><em>Jatamansi Taila Shirodhara</em> was found to be effective in relieving symptoms of Anxiety and Psychological distress (<em>Chittodvega</em>) immediately after the procedure, viz. sleep disturbance, difficulty in concentration, and fearfulness. <em>Jatamansi Taila Shirodhara</em> was found to be highly effective in improving Quality of Life (QoL), especially in improving functional ability, well-being and reducing symptomatology related to breast cancer, measured by scores of QLQ C30 and symptom score of QLQ BR23.</div></div><div><h3>Conclusion</h3><div>This study emphasizes the role of <em>Jatamansi Taila Shirodhara</em> therapy for mind and body relaxation in psychological distress seen in breast cancer especially, in TNBC patients.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"16 1","pages":"Article 101069"},"PeriodicalIF":1.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143059091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chittodvega, classified as a Mano-Vikara (psychological disorder) in Ayurveda, can be correlated with general anxiety disorder. The disturbance of Vata Dosha plays a critical role in its manifestation. Ayurvedic treatments such as Abhyanga (oleation) and Shirodhara (dripping of medicated oil or other suitable liquid on forehead) are known to pacify Vata. Abhyanga helps to stabilize the body, while Shirodhara enhances concentration, promoting mental stability. Both procedures synergistically balance VataDosha, addressing the physiological and psychological aspects of Chittodvega.A 50-year-old male patient presented with complaints of anxiety at Ch. Brahm Prakash Ayurveda Charak Sansthan, New Delhi. He underwent a 14-day treatment regimen, including 7 days of hospitalization and 7 days of follow-up. The treatment involved Abhyanga(Oleation) with Til Taila (sesame oil) and Shirodhara with Dashmool Siddha Ksheer (herbal milk decoction), aimed at assessing their impact on serum cortisol levels. Both, morning and evening cortisol level of this patient was within the normal range before and after the treatment. This study was done only to check the effectiveness of Abhyanga and Shirodhara on serum cortisol level. Observable changes were found in serum cortisol along with a reduction in the patient's anxiety symptoms, demonstrating the efficacy of these Ayurvedic interventions in managing Chittodvega.
{"title":"Role of Shirodhara and Abhyanga on serum cortisol in Anxiety – A case report","authors":"Ashu Sharma , Megha Sugandh , Atul Bhardwaj , Arun Gupta","doi":"10.1016/j.jaim.2024.100948","DOIUrl":"10.1016/j.jaim.2024.100948","url":null,"abstract":"<div><div><em>Chittodvega</em>, classified as a <em>Mano-Vikara</em> (psychological disorder) in <em>Ayurveda</em>, can be correlated with general anxiety disorder. The disturbance of <em>Vata Dosha</em> plays a critical role in its manifestation. <em>Ayurvedic</em> treatments such as <em>Abhyanga</em> (oleation) and <em>Shirodhara</em> (dripping of medicated oil or other suitable liquid on forehead) are known to pacify <em>Vata</em>. <em>Abhyanga</em> helps to stabilize the body, while <em>Shirodhara</em> enhances concentration, promoting mental stability. Both procedures synergistically balance <em>Vata</em> <em>Dosha</em>, addressing the physiological and psychological aspects of <em>Chittodvega</em>.A 50-year-old male patient presented with complaints of anxiety at Ch. Brahm Prakash Ayurveda Charak Sansthan, New Delhi. He underwent a 14-day treatment regimen, including 7 days of hospitalization and 7 days of follow-up. The treatment involved Abhyanga(Oleation) with Til Taila (sesame oil) and <em>Shirodhara</em> with <em>Dashmool Siddha Ksheer</em> (herbal milk decoction), aimed at assessing their impact on serum cortisol levels. Both, morning and evening cortisol level of this patient was within the normal range before and after the treatment. This study was done only to check the effectiveness of <em>Abhyanga</em> and <em>Shirodhara</em> on serum cortisol level. Observable changes were found in serum cortisol along with a reduction in the patient's anxiety symptoms, demonstrating the efficacy of these <em>Ayurvedic</em> interventions in managing <em>Chittodvega</em>.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"16 1","pages":"Article 100948"},"PeriodicalIF":1.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11773008/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142971006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号